Giusti Massimo, Sidoti Marilena
Endocrine Unit, Priamar Clinical-Diagnostic Centre, Savona, Italy.
Local Health Service 2 Savonese, Liguria Region, Sidoti, Italy.
Thyroid Res. 2022 Nov 2;15(1):21. doi: 10.1186/s13044-022-00139-z.
Clinicians should be aware that subacute thyroiditis (SAT) might be an under-reported adverse effect of COVID-19 vaccines.
In records from endocrinological examinations, we reviewed the incidence of diagnoses of SAT from 2000 to 2020 and during the 2021 COVID-19 vaccination campaign.
Review of electronic records from June to December in each year from 2000 to 2021.
From 2000 to 2020, 51 patients in our centre had SAT (0.6%). From June to December 2021, 7 females were diagnosed with SAT after vaccination. The percentage of SAT in 2021 medical files was 1.5%. SAT diagnoses significantly (P = 0.03) increased in 2021 in comparison with the 2000-2020 period. The median age of SAT patients in 2021 (51 years; IQR 35-66 years) was higher than in the 2000-2020 period (45 years, IQR 38-52 years; P = 0.05).
To date, few cases of SAT after COVID-19 vaccinations have been described in the literature, with sub-clinical, normal or increased thyroid function during 1-3-month follow-up. Our findings indicate that SAT after COVID-19 vaccination occurs more frequently than in other virus-related cases and at a greater age. Our observation of a local increase in SAT during the 2021 COVID-19 vaccination campaign indicates that physicians should be aware of this infrequent side effect, which must be considered and monitored after COVID-19 vaccination.
临床医生应意识到亚急性甲状腺炎(SAT)可能是新冠疫苗未被充分报告的不良反应。
在内分泌检查记录中,我们回顾了2000年至2020年以及2021年新冠疫苗接种期间SAT的诊断发生率。
回顾2000年至2021年每年6月至12月的电子记录。
2000年至2020年,我们中心有51例SAT患者(0.6%)。2021年6月至12月,7名女性在接种疫苗后被诊断为SAT。2021年医疗档案中SAT的比例为1.5%。与2000 - 2020年期间相比,2021年SAT诊断显著增加(P = 0.03)。2021年SAT患者的中位年龄(51岁;四分位间距35 - 66岁)高于2000 - 2020年期间(45岁,四分位间距38 - 52岁;P = 0.05)。
迄今为止,文献中描述的新冠疫苗接种后SAT病例较少,在1 - 3个月的随访期间甲状腺功能为亚临床、正常或升高。我们的研究结果表明,新冠疫苗接种后SAT的发生比其他病毒相关病例更频繁,且发病年龄更大。我们观察到2021年新冠疫苗接种期间SAT在当地有所增加,这表明医生应意识到这种罕见的副作用,在新冠疫苗接种后必须予以考虑和监测。